George Z. Retsch-Bogart, MD

1. The Best Doctors in America®, 2005-2009


2. Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation, 1989


3. Thomas H. Davis Fellowship, American Lung Association of North Carolina, 1988


4. Research Award, University of North Carolina Department of Pediatrics, 1988

1. Eradication of initial Pseudomonas aeruginosa infection in children with Cystic Fibrosis – What is the optimal treatment approach?
   Authors: Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
   Pediatr Pulmonol 2007 42(9): 104-12., 2007


2. Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
   Authors: McCoy KS, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, AB Montgomery
   Am J Respir Crit Care Med. 2008, 178: 921-928. , 2008


3. A Phase 2 study of Aztreonam Lysinate for Inhalation to treat cystic fibrosis patients with Pseudomonas aeruginosa infection
   Authors: Retsch-Bogart GZ, Burns J, Markus R, Gibson R for the CF TDN Aztreonam for Inhalation Phase 2 Study Group
   Pediatr Pulmonol 2008, 43:47-58., 2008


4. Early anti-pseudomonal intervention in young patients with cystic fibrosis (EPIC): rationale and design of the clinical trial and observational study
   Authors: Treggiari M, Rosenfeld M, Retsch-Bogart G, Gibson RL, Meyer-Hamblett N, Williams J, Emerson J, Kronmal R, Ramsey B for the EPIC Study Group
   Contemp Clin Trials. 2009; 30: 256-268., 2009


5. Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
   Authors: Retsch-Bogart GZ, AL Quittner. RL Gibson, CM Oermann, KS McCoy, AB Montgomery, PJ Cooper
   Chest. 2009; 135: 1223-1232. , 2009


6. Update on Cystic Fibrosis-Related Bone Disease: A Special Focus on Children
   Authors: Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM
   Paediatr Respir Rev. 2009; 10:134-142., 2009


7. Update on new pulmonary therapies
   Authors: Retsch-Bogart GZ
   Curr Opin Pulm Med. 2009 Aug 19. [Epub ahead of print]., 2009

1. Sustained Improvement In Pulmonary Function Following A 28-day Course Of 75 mg AZLI TID Therapy
   Authors: G Retsch-Bogart, K McCoy, RL Gibson, C Oermann, M Braff, AB Montgomery
   Pediatr Pulmonol 2008., 2008


2. Source of Improvements in Lung Function in Patients with Cystic Fibrosis (CF) Following Treatment with Aztreonam Lysine for Inhalation (AZLI)
   Authors: G Retsch-Bogart, K McCoy, R Gibson, C Oermann, AB Montgomery
   Pediatr Pulmonol 2008., 2008


3. Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006
   Authors: Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Montgomery AB J Cystic Fibrosis, 2009, A107
   J Cystic Fibrosis, 2009, A107., 2009


4. Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)
   Authors: McCoy KS, Retsch-Bogart GZ, Gibson RL, Oermann CM, McKevitt M, Montgomery AB
   J Cystic Fibrosis, 2009, A108., 2009


5. Adherence over multiple courses of Aztreonam Lysine for Inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
   Authors: Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Quittner, AL, Montgomery AB
   J Cystic Fibrosis, 2009, A109., 2009